Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 7Unknown 2Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Sarcoma 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 215Uterine Cervical Neoplasms 144Endometrial Neoplasms 111Fallopian Tube Neoplasms 78Breast Neoplasms 59Carcinoma, Non-Small-Cell Lung 43Colorectal Neoplasms 40Stomach Neoplasms 35Melanoma 31Carcinoma, Renal Cell 29Prostatic Neoplasms 28Neoplasms 28Carcinoma, Ovarian Epithelial 28Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Esophageal Neoplasms 25Neoplasm Metastasis 24Lung Neoplasms 23Urinary Bladder Neoplasms 22Head and Neck Neoplasms 21Colonic Neoplasms 20Vulvar Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Transitional Cell 14Carcinoma, Hepatocellular 14Uterine Neoplasms 13Small Cell Lung Carcinoma 13Sarcoma 13Rectal Neoplasms 12Peritoneal Neoplasms 12

Interventions

niraparib 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Disease Progression × Gynecologic × Clear all
NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
31 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡